INFOGRAPHIC: Regeneron's 2Q Eylea gains, pipeline catalysts
This article was originally published in Scrip
Executive Summary
Regeneron Pharmaceuticals is riding high based on the Tarrytown, New York-based company's 45% rise in second quarter revenue to $666m versus the same period last year and a 53% jump in global Eylea (aflibercept) sales to $662m.